var data={"title":"Levofloxacin (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levofloxacin (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389801?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levofloxacin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Levofloxacin (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=levofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levofloxacin (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398365\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious adverse reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue levofloxacin immediately and avoid the use of fluoroquinolones in patients who experience any of these serious adverse reactions. Because fluoroquinolones have been associated with serious adverse reactions, reserve levofloxacin for use in patients who have no alternative treatment options for the following indications: uncomplicated urinary tract infection, acute bacterial exacerbation of chronic bronchitis, and acute bacterial sinusitis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exacerbation of myasthenia gravis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398376\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Levaquin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398377\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Levaquin;</li>\n      <li>Levaquin in 5% Dextrose Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501846\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Quinolone</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501924\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=levofloxacin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Levofloxacin (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Concentration of oral suspension may vary (commercially available or extemporaneous compounded); use caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> In pediatric patients, fluoroquinolones are not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for situations where no safe and effective substitute is available (eg, multidrug resistance) or in situations where the only alternative is parenteral therapy and levofloxacin offers an oral therapy option (AAP [Jackson 2016]). Use of levofloxacin in infants &lt;6 months has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection (AAP [Jackson 2016]):</b> Infants &ge;6 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">6 months to &lt;5 years: Oral, IV: 8 to 10 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;5 years: Oral, IV: 10 mg/kg/dose once daily; maximum dose: 750 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax, inhalational (postexposure prophylaxis):</b> Infants &ge;6 months, Children, and Adolescents: <b>Note:</b> Begin therapy as soon as possible after exposure:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;50 kg: Oral, IV: 8 mg/kg/dose every 12 hours for 60 days; maximum dose: 250 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;50 kg: Oral, IV: 500 mg every 24 hours for 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Infants, Children, and Adolescents: Oral: 10 mg/kg/dose every 48 hours; maximum initial dose: 500 mg; maximum subsequent doses: 250 mg (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Chlamydia trachomatis, </i>urogenital infections: </b>Adolescents: Oral: 500 mg every 24 hours for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis pulmonary exacerbation:</b> Limited data available (Chmiel 2014): Infants &ge;6 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">6 months to &lt;5 years: Oral, IV: 10 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;5 years: Oral, IV: 10 mg/kg/dose once daily; maximum dose: 750 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epididymitis, nongonococcal:</b> Adolescents: Oral: 500 mg once daily for 10 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Mycobacterium avium Complex</i></b>\n      <b>, severe or disseminated disease, HIV-exposed/-positive</b>: Adolescents: Oral: 500 mg once daily in combination with other antibiotics (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease:</b> Adolescents: Oral: 500 mg once daily for 14 days with or without concomitant metronidazole; <b>Note:</b> Due to resistant organisms, the CDC recommends use as an alternative therapy only if standard parenteral cephalosporin therapy is not feasible and community prevalence, and individual risk of quinolone-resistant gonococcal organisms is low. Culture sensitivity must be confirmed (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague <i>(Yersinia pestis)</i>, prophylaxis or treatment:</b> Infants &ge;6 months, Children, and Adolescents: <b>Note:</b> Begin therapy as soon as possible after exposure:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;50 kg: Oral, IV: 8 mg/kg/dose every 12 hours for 10 to 14 days; maximum dose: 250 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;50 kg: Oral, IV: 500 mg every 24 hours for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired (CAP)</b> (IDSA/PIDS [Bradley 2011]): <b>Note:</b> May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. Levofloxacin is not the preferred agent for CAP but may be used as an alternative agent when necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Typical pathogens (eg, H. influenza, S. pneumoniae): </i>\n      <b>Note:</b> Oral administration is generally reserved for mild infections or step down therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months and Children &lt;5 years: Oral, IV: 8 to 10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years and Adolescents &le;16 years: Oral, IV: 8 to 10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Atypical pathogens (eg, <i>Mycoplasma pneumonia</i> or <i>Chlamydia ssp</i>):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;6 months and Children &lt;5 years: IV: 8 to 10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;5 years and Adolescents &le;16 years: IV: 8 to 10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Mild infection/step-down therapy: Adolescents with skeletal maturity: Oral: 500 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rhinosinusitis, acute bacterial: Note:</b> Recommended in the following types of patients: Type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow 2012). Children and Adolescents: Oral, IV: 10 to 20 mg/kg/<b>day</b> divided every 12 to 24 hours for 10 to 14 days; maximum daily dose: 500 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical prophylaxis:</b> Children and Adolescents: IV: 10 mg/kg as a single dose 120 minutes prior to procedure; maximum dose: 500 mg/dose; <b>Note:</b> While fluoroquinolones have been associated with an increased risk of tendinitis/tendon rupture in all ages, use of these agents for single-dose prophylaxis is generally safe (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis, multidrug-resistant:</b> Limited data available: <b>Note:</b> Use in combination with at least 2 to 3 additional anti-TB agents (overall multidrug regimen dependent upon susceptibility profile/patterns) (Seddon 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;5 years: Oral: 7.5 to 10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years and Adolescents: Oral: 7.5 to 10 mg/kg/dose every 24 hours; maximum daily dose: 750 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urethritis, nongonococcal:</b> Adolescents: Oral: 500 mg every 24 hours for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult: <b>Note:</b> Sequential therapy (intravenous to oral) may be instituted based on prescriber's discretion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax, postexposure (inhalation):</b> Oral, IV: 500 mg every 24 hours for 60 days beginning as soon as possible after exposure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchitis, chronic (acute bacterial exacerbation):</b> Oral, IV: 500 mg every 24 hours for at least 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Chlamydia trachomatis</i> urogenital infections:</b> Oral: 500 mg every 24 hours for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epididymitis, nongonococcal:</b> Oral: 500 mg once daily for 10 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague<i> (Yersinia pestis)</i>, prophylaxis or treatment:</b> Oral, IV: 500 mg every 24 hours for 10 to 14 days, beginning as soon as possible after exposure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia:</b> Oral, IV: 500 mg every 24 hours for 7 to 14 days or 750 mg every 24 hours for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostatitis, chronic bacterial:</b> Oral, IV: 500 mg every 24 hours for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rhinosinusitis, acute bacterial:</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's recommendations: 500 mg every 24 hours for 10 to 14 days or 750 mg every 24 hours for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations: 500 mg every 24 hours for 5 to 7 days (Chow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Oral, IV:</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">Complicated: 750 mg every 24 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Uncomplicated: 500 mg every 24 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urethritis, nongonococcal:</b> Oral: 500 mg every 24 hours for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection (UTI):</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Complicated or acute pyelonephritis: 250 mg every 24 hours for 10 days or 750 mg every 24 hours for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Uncomplicated: 250 mg every 24 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: IV, Oral: The following adjustments have been recommended (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 5 to 10 mg/kg/dose every 12 hours in ages &le;5 years and 5 to 10 mg/kg/dose every 24 hours in ages &gt;5 years.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 5 to 10 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 5 to 10 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: 5 to 10 mg/kg/dose every 48 hours; not removed by hemodialysis; supplemental levofloxacin doses are not required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 5 to 10 mg/kg/dose every 48 hours; not removed by peritoneal dialysis; supplemental levofloxacin doses are not required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 10 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Normal renal function dosing of 250 mg/day:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 49 mL/minute: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 19 mL/minute: Administer 250 mg every 48 hours (except in uncomplicated UTI, where no dosage adjustment is required)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis (administer after hemodialysis on dialysis days)/peritoneal dialysis (PD): No information available</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Normal renal function dosing of 500 mg/day:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 49 mL/minute: Administer 500 mg initial dose, followed by 250 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 19 mL/minute: Administer 500 mg initial dose, followed by 250 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis (administer after hemodialysis on dialysis days)/peritoneal dialysis (PD): Administer 500 mg initial dose, followed by 250 mg every 48 hours; not removed by hemodialysis or peritoneal dialysis; supplemental levofloxacin doses are not required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Normal renal function dosing of 750 mg/day:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 49 mL/minute: Administer 750 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 19 mL/minute: Administer 750 mg initial dose, followed by 500 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis (administer after hemodialysis on dialysis days)/peritoneal dialysis (PD): Administer 750 mg initial dose, followed by 500 mg every 48 hours; not removed by hemodialysis or peritoneal dialysis; supplemental levofloxacin doses are not required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Normal renal function dosing of 750 or 1,000 mg daily (treatment of tuberculosis <b>only</b>) (CDC 2003): CrCl &lt;30 mL/minute: Administer 750 or 1,000 mg 3 times per week (in hemodialysis patients administer after dialysis on dialysis days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH: Loading dose of 500 to 750 mg followed by 250 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHD: Loading dose of 500 to 750 mg followed by 250 to 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHDF: Loading dose of 500 to 750 mg followed by 250 to 750 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; has not been studied; however, dosage adjustment unlikely to be necessary due to limited hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8408135\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/50 mL (50 mL); 500 mg/100 mL (100 mL); 750 mg/150 mL (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levaquin: 250 mg/50 mL (50 mL [DSC]); 500 mg/100 mL (100 mL [DSC]); 750 mg/150 mL (150 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/50 mL (50 mL); 500 mg/100 mL (100 mL); 750 mg/150 mL (150 mL); 25 mg/mL (20 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levaquin: 25 mg/mL (480 mL [DSC]) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (10 mL, 20 mL, 100 mL, 200 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levaquin: 250 mg, 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg, 750 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398378\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398367\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088619.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlGSE/KOjq2DWQecSYk0SGkg==&amp;TOPIC_ID=16013\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088619.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501964\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Tablets may be administered without regard to meals; oral solution should be administered 1 hour before or 2 hours after meals. Administer at least 2 hours before or 2 hours after antacids containing magnesium or aluminum, sucralfate, metal cations (eg, iron), multivitamin preparations with zinc, or didanosine chewable/buffered tablets or the pediatric powder for solution. Maintain adequate hydration to prevent crystalluria or cylindruria.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer by slow IV infusion over 60 to 90 minutes (250 to 500 mg over 60 minutes; 750 mg over 90 minutes); avoid rapid or bolus IV infusion due to risk of hypotension. Avoid administration through an intravenous line with a solution containing multivalent cations (eg, magnesium, calcium). Maintain adequate hydration to prevent crystalluria or cylindruria; not for IM, SubQ, or intrathecal administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8404706\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution for injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vial: Store at room temperature. Protect from light. Diluted solution (5 mg/mL) is stable in NS, D5W, D5NS, D5LR, D5<sup>1</sup>/<sub>2</sub>NS with 20 mEq/L KCl, Plasma-Lyte 56 in D5, or sodium lactate for 72 hours when stored at room temperature; stable for 14 days when stored under refrigeration. When frozen, stable for 6 months; do not refreeze. Do not thaw in microwave or by bath immersion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Premixed: Store at &le;25&deg;C (77&deg;F); do not freeze. Brief exposure to 40&deg;C (104&deg;F) does not adversely affect the product. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, oral solution: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501903\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment and prophylaxis of plague and postexposure prevention of inhalational anthrax (FDA approved for ages &ge;6 months and adults); treatment of acute bacterial sinusitis, pneumonia (nosocomial and community acquired), acute bacterial exacerbation of chronic bronchitis, skin and skin structure infections (uncomplicated or complicated), chronic bacterial prostatitis, urinary tract infections (uncomplicated or complicated), and acute pyelonephritis (FDA approved in ages &ge;18 years and adults). Has also been used to treat pulmonary exacerbations in cystic fibrosis, multidrug-resistant tuberculosis, and exit-site or tunnel infection in patients with peritoneal dialysis catheters.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note: </b>Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects), reserve levofloxacin for use in all patients including pediatric patients (AAP [Jackson 2016]) who have no alternative treatment options (eg, acute exacerbation of chronic bronchitis, acute bacterial sinusitis, and uncomplicated urinary tract infections in adults).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398366\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levaquin may be confused with Levoxyl, Levsin/SL, Lovenox</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LevoFLOXacin may be confused with levETIRAcetam, levodopa, Levophed, levothyroxine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Levaquin [Argentina, Brazil, U.S., Venezuela] may be confused with Lariam brand name for mefloquine [multiple international markets]  </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8401456\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal electroencephalogram, abnormal gait, acute generalized exanthematous pustolosis, acute renal failure, ageusia, agranulocytosis, anaphylactoid reaction, anemia (including aplastic and hemolytic), anorexia, anosmia, brain disease (rare), cardiac arrest, cardiac arrhythmia (including ventricular tachycardia/fibrillation and torsades de pointes), casts in urine, <i>Clostridium difficile</i>-associated diarrhea, confusion, convulsions, crystalluria, depression, elevation in serum levels of skeletal-muscle enzymes, eosinophilia, epistaxis, erythema multiforme, esophagitis, exacerbation of myasthenia gravis, gastritis (including gastroenteritis), glossitis, granulocytopenia, hallucination, hepatic failure (some fatal), hepatic insufficiency, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperglycemia, hyperkalemia, hyperkinesias, hypersensitivity reaction (including anaphylaxis, angioedema, rash, pneumonitis, and serum sickness), hypertension, hypertonia, hypoacusis, hypoglycemia, hypotension, increased INR, increased intracranial pressure, increased serum alkaline phosphatase, increased serum transaminases, interstitial nephritis, intestinal obstruction, jaundice, leukocytosis, leukopenia, leukorrhea, lymphadenopathy, multiorgan failure, muscle injury, muscle spasm, pancreatitis, pancytopenia, paralysis, paranoia, peripheral neuropathy (may be irreversible), phlebitis, phototoxicity, prolonged prothrombin time, prolonged Q-T interval on ECG, pseudotumor cerebri, psychosis, renal function abnormality, rhabdomyolysis, rupture of tendon, scotoma, seizure, skeletal pain, skin photosensitivity, sleep disorder (including abnormal dreams and nightmares), Stevens-Johnson syndrome, stomatitis, suicidal ideation, syncope, tachycardia, tendonitis, toxic epidermal necrolysis, toxic psychosis, thrombocytopenia (including thrombotic thrombocytopenic purpura), uveitis, vasculitis (leukocytoclastic), vasodilatation, visual disturbances(including diplopia), voice disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8401447\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to levofloxacin, any component of the formulation, or other quinolones</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): History of tendonitis or tendon rupture associated with use of any quinolone antimicrobial agent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8401448\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: Fluoroquinolones may prolong QT<sub>c</sub> interval; avoid use in patients with a history of QT<sub>c</sub> prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Unrelated to hypersensitivity, severe hepatotoxicity (including acute hepatitis and fatalities) has been reported. Elderly patients may be at greater risk. Discontinue therapy immediately if signs and symptoms of hepatitis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions. Discontinue use if photosensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serious adverse reactions:<b>[US Boxed Warning]: Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue levofloxacin immediately and avoid use of fluoroquinolones in patients who experience any of these serious adverse reactions.</b> Patients of any age or without preexisting risk factors have experienced these reactions; may occur within hours to weeks after initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- CNS effects: Fluoroquinolones have been associated with an increased risk of CNS effects including seizures, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis; may also cause nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or actions. May occur following the first dose; discontinue immediately and avoid further use of fluoroquinolones in patients who experience these reactions. Use with caution in patients with known or suspected CNS disorder, or risk factors that may predispose to seizures or lower the seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Peripheral neuropathy: Fluoroquinolones have been associated with an increased risk of peripheral neuropathy; may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur. Avoid use in patients who have previously experienced peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Tendinitis/tendon rupture: Fluoroquinolones have been associated with an increased risk of tendonitis and tendon rupture in all ages; risk may be increased with concurrent corticosteroids, solid organ transplant recipients, and in patients &gt;60 years of age, but has also occurred in patients without these risk factors. Rupture of the Achilles tendon has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps, hand) have also been reported. Inflammation and rupture may occur bilaterally. Cases have been reported within hours or days of initiation, and up to several months after discontinuation of therapy. Strenuous physical activity, renal failure, and previous tendon disorders may be independent risk factor for tendon rupture. Discontinue at first sign of tendon pain, swelling, inflammation or rupture. Avoid use in patients with a history of tendon disorders or who have experienced tendinitis or tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: <b>[US Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis; avoid use in patients with known history of myasthenia gravis.</b> Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Adverse effects (eg, hepatotoxicity, tendon rupture, QT changes) may be increased in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Safety of use in pediatric patients for &gt;14 days of therapy has not been studied; increased incidence of musculoskeletal disorders (eg, arthralgia, tendon rupture) has been observed in children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Reserve use of levofloxacin for treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, or uncomplicated urinary tract infection for patients who have no alternative treatment options because of the risk of disabling and potentially serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects).</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022082\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Increased osteochondrosis in immature rats and dogs was observed with levofloxacin and fluoroquinolones have caused arthropathy with erosions of the cartilage in weight-bearing joints of immature animals. In a pooled safety data analysis of more than 2,500 pediatric patients (6 months to 16 years), musculoskeletal events (eg, tendinopathy [inflammation or tendon rupture], arthritis [joint inflammation with redness and/or swelling], arthralgia [pain], or gait abnormality [limping, refusal to walk]) were observed more frequently at 2 months and 12 months after treatment with levofloxacin than comparative treatment; the most frequently reported event was joint pain (85%). No physical joint abnormalities were observed; however, cumulative long-term (up to 5 years) outcomes showed musculoskeletal adverse events (including ongoing arthropathy; peripheral neuropathy; abnormal bone development; scoliosis; walking difficulty; myalgia; tendon disorder; hypermobility syndrome; or pain in the spine, shoulder, or hip) were slightly higher in the comparator group than levofloxacin. Safety of use in pediatric patients for &gt;14 days of therapy has not reported; in available pediatric safety data, the typical duration of therapy was approximately 10 days (CAP, AOM) (AAP [Jackson 2016]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In pediatric patients, fluoroquinolones are not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for situations where no safe and effective substitute is available (eg, multidrug resistance) or in situations where the only alternative is parenteral therapy and levofloxacin offers an oral therapy option (AAP [Jackson 2016]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Concentration of oral suspension may vary (commercially available or extemporaneous compound); use caution. Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299595\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8401459\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16013&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Quinolones may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents.<b> Exceptions: </b>Calcium Chloride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heroin: Quinolones may enhance the adverse/toxic effect of Heroin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Quinolones. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the absorption of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): LevoFLOXacin (Systemic) may enhance the QTc-prolonging effect of Tacrolimus (Systemic). LevoFLOXacin (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Quinolones may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51073434\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Administration with food prolonged time to peak by ~1 hour and decreased the peak concentration by ~14% and ~25% for the tablet and oral solution, respectively. Management: Tablet may be administered without regard to food; oral solution should be administered at least 1 hour before or 2 hours after food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8400751\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8400752\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Levofloxacin crosses the placenta and can be detected in the amniotic fluid and cord blood (Ozy&uuml;nc&uuml; 2010a; Ozy&uuml;nc&uuml; 2010b). Information specific to levofloxacin use during pregnancy is limited (Padberg 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501965\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Evaluation of organ system functions (renal, hepatic, and hematopoietic) is recommended periodically during therapy; the possibility of crystalluria should be assessed, hydration status; WBC and signs of infection; number and type of stools/day for diarrhea; signs and symptoms of tendonitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8404710\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As the S(-) enantiomer of the fluoroquinolone, ofloxacin, levofloxacin, inhibits DNA-gyrase in susceptible organisms thereby inhibits relaxation of supercoiled DNA and promotes breakage of DNA strands. DNA gyrase (topoisomerase II), is an essential bacterial enzyme that maintains the superhelical structure of DNA and is required for DNA replication and transcription, DNA repair, recombination, and transposition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8404755\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and complete; levofloxacin oral tablet and solution formulations are bioequivalent </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed in the body, including blister fluid, skin tissue, macrophages, prostate, and lung tissue; CSF concentrations ~15% of serum concentrations </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">V<sub>d</sub>: (Chien 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &ge;6 months, Children, and Adolescents &le;16 years: Mean range: 1.44 to 1.57 L/kg; reported values not statistically different between pediatric age subgroups; distribution not age-dependent </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 1.27 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~24% to 38%; primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimally hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &ge;6 months and Children &le;5 years: ~4 hours (Chien 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 5 to 10 years: 4.8 hours (Chien 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 10 to 12 years: 5.4 hours (Chien 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 12 to 16 years: 6 hours (Chien 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults, renal impairment: 27 &plusmn; 10 hours (CrCl 20 to 49 mL/minute); 35 &plusmn; 5 hours (CrCl &lt;20 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~87% as unchanged drug, &lt;5% as metabolites); feces (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: IV (Chien 2005): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 6 months to 2 years: 0.35 &plusmn; 0.13 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 5 years: 0.32 &plusmn; 0.08 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 5 to 10 years: 0.25 &plusmn; 0.05 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 10 to 12 years: 0.19 &plusmn; 0.05 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 12 to 16 years: 0.18 &plusmn; 0.03 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.15 &plusmn; 0.02 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11432885\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Commercial oral solution is available (25 mg/mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 50 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Plus&reg; and strawberry syrup NF. Crush six 500 mg levofloxacin tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 60 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label &quot;shake well&quot;. Stable for 57 days when stored in amber plastic prescription bottles at room temperature or refrigerated.</p>\n    <div class=\"reference\">VandenBussche HL, Johnson CE, and Fontana EM, et al, &quot;Stability of Levofloxacin in an Extemporaneously Compounded Oral Liquid,&quot; <i>Am J Health Syst Pharm</i>, 1999, 56(22):2316-8.<span class=\"pubmed-id\">10582824</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8408137\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevoFLOXacin in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/50 mL (50 mL): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL (100 mL): $7.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg/150 mL (150 mL): $7.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevoFLOXacin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (20 mL): $19.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevoFLOXacin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (10 mL): $15.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Levaquin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (50): $1,572.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $1,802.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (20): $1,349.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LevoFLOXacin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (50): $840.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $963.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (20): $721.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961985\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adlox (IN);</li>\n      <li>Amlevo (VN);</li>\n      <li>Astefor (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Auxxil (CL, PY);</li>\n      <li>Avoxin (JO);</li>\n      <li>Axoflon (PH);</li>\n      <li>Bacflocin (TW);</li>\n      <li>Bactevo (VN);</li>\n      <li>Bredelin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Conlevo (EC);</li>\n      <li>Corvox (ID);</li>\n      <li>Cravit (CN, HK, ID, JP, MY, PK, SG, TH, TW, VN);</li>\n      <li>Cravox (ID);</li>\n      <li>Elequine (BB, BM, BS, EC, JM, NL, PR, SR, TT);</li>\n      <li>Evocs-III (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Evolox (RO);</li>\n      <li>Evoxil (MT);</li>\n      <li>Fenalex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Flexid (HR);</li>\n      <li>Floxacap (ID);</li>\n      <li>Floxel (PH);</li>\n      <li>Getzlox (VN);</li>\n      <li>Glevo (ZW);</li>\n      <li>Glevo IV (PH);</li>\n      <li>Gravixin (TH);</li>\n      <li>Hailon (CN);</li>\n      <li>Lamiwin (TZ);</li>\n      <li>Lecifex (VN);</li>\n      <li>Lecrav (ID);</li>\n      <li>Lectacin (VN);</li>\n      <li>Leflodal (TW);</li>\n      <li>Leflox (BD);</li>\n      <li>Lefloxin (TH);</li>\n      <li>Lefocin (KR);</li>\n      <li>Lemed (HK);</li>\n      <li>LEO (BD);</li>\n      <li>Leroxacin (KR);</li>\n      <li>Lesacin (KR);</li>\n      <li>Levaquin (AR, BR, CO, PE);</li>\n      <li>Levo (IL);</li>\n      <li>Levobact (PH);</li>\n      <li>Levocin (ID, PH, TH);</li>\n      <li>Levoflox (QA, ZW);</li>\n      <li>Levokacin (KR);</li>\n      <li>Levoksa (UA);</li>\n      <li>Levomac (ET, ZW);</li>\n      <li>Levomicin (KR);</li>\n      <li>Levon (PH);</li>\n      <li>Levoquin (HK, PH);</li>\n      <li>Levores (ID);</li>\n      <li>Levotsyn (UA);</li>\n      <li>Levox (JO, LK, PH, QA, ZW);</li>\n      <li>Levoxa (MT);</li>\n      <li>Levoxacin (IT);</li>\n      <li>Levoxin (HK);</li>\n      <li>Levoxl (HK);</li>\n      <li>Levunid (PE);</li>\n      <li>Lexacin (HK);</li>\n      <li>Lexlo (BD);</li>\n      <li>Locikline (MY);</li>\n      <li>Lovequin (ID);</li>\n      <li>Loxof (LB);</li>\n      <li>Lufi (LK);</li>\n      <li>LUFI-500 (SG);</li>\n      <li>Matador (LB);</li>\n      <li>Mosardal (ID);</li>\n      <li>Nexquin (TZ);</li>\n      <li>Nirliv (TH);</li>\n      <li>Nirlix (LK);</li>\n      <li>Nislev (ID);</li>\n      <li>Nofaxin (KR);</li>\n      <li>Olfovel (TH);</li>\n      <li>Omnivox (PH);</li>\n      <li>Pneumocal (PH);</li>\n      <li>Ponaris (PE);</li>\n      <li>Quinomed L (AR);</li>\n      <li>Qure (ET);</li>\n      <li>Reskuin (ID);</li>\n      <li>Resquin (LK);</li>\n      <li>Rinvox (ID);</li>\n      <li>Rozoxin (TW);</li>\n      <li>Tavager (IE);</li>\n      <li>Tavanic (AE, AR, AT, BE, BG, BH, BM, BS, CH, CL, CR, CY, CZ, DE, DO, EE, EG, ES, FI, FR, GB, GT, HN, IE, IL, JM, JO, KW, LB, LT, LU, MT, NI, NL, PA, PE, PL, PT, PY, QA, RO, SA, SE, SK, SV, VE);</li>\n      <li>Truxa (EC, UY);</li>\n      <li>Uroflox (EC);</li>\n      <li>Vocin (TH);</li>\n      <li>Voflox (TH);</li>\n      <li>Volequin (ID);</li>\n      <li>VoLox (ID);</li>\n      <li>Vorotal (TW);</li>\n      <li>Wilovex (PH);</li>\n      <li>Xalecin (TH);</li>\n      <li>Zidalex (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &quot;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&quot; <i>Surg Infect (Larchmt)</i>, 2013, 14(1):73-156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23461695/pubmed\" target=\"_blank\" id=\"23461695\">23461695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cahill JB Jr, Bailey EM, Chien S, et al, &quot;Levofloxacin Secretion in Breast Milk: A Case Report,&quot; <i>Pharmacotherapy</i>, 2005, 25(1):116-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15767227/pubmed\" target=\"_blank\" id=\"15767227\">15767227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chien S, Wells TG, Blumer JL, et al, &ldquo;Levofloxacin Pharmacokinetics in Children,&rdquo; <i>J Clin Pharmacol</i>, 2005, 45(2):153-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15647407 /pubmed\" target=\"_blank\" id=\"15647407 \">15647407 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chmiel JF, Aksamit TR, Chotirmall SH, et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. <i>Ann Am Thorac Soc</i>. 2014;11(7):1120-1129.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/25102221/pubmed\" target=\"_blank\" id=\"25102221\">25102221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &quot;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&quot; <i>Clin Infect Dis</i>, 2012, 54(8):72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ernst ME, Ernst EJ, and Klepser ME, &ldquo;Levofloxacin and Trovafloxacin: The Next Generation of Fluoroquinolones?&rdquo; <i>Am J Health Syst Pharm</i>, 1997, 54(22):2569-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/9397218/pubmed\" target=\"_blank\" id=\"9397218\">9397218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections (OIs) in HIV-Exposed and HIV-Infected Children. December 2016. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jackson MA, Schutze GE, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. <i>Pediatrics</i>. 2016;138(5).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27940800/pubmed\" target=\"_blank\" id=\"27940800\">27940800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan YC, Koren G. Use of ciprofloxacin during breastfeeding. <i>Can Fam Physician</i>. 2015;61(4):343-344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26052598/pubmed\" target=\"_blank\" id=\"26052598\">26052598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levaquin (levofloxacin systemic) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozy&uuml;nc&uuml; O, Beksac MS, Nemutlu E, Katlan D, Kir S. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. <i>J Obstet Gynaecol Res</i>. 2010;36(3):484-487.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/20598025 /pubmed\" target=\"_blank\" id=\"20598025 \">20598025 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozy&uuml;nc&uuml; O, Nemutlu E, Katlan D, Kir S, Beksac MS. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. <i>Int J Antimicrob Agents</i>. 2010;36(2):175-178.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/20418070 /pubmed\" target=\"_blank\" id=\"20418070 \">20418070 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24841264 /pubmed\" target=\"_blank\" id=\"24841264 \">24841264 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaad UB, &ldquo;Role of the New Quinolones in Pediatric Practice,&rdquo; <i>Pediatr Infect Dis J</i>, 1992, 11(12):1043-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/1461695 /pubmed\" target=\"_blank\" id=\"1461695 \">1461695 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seddon JA, Furin JJ, Gale M, et al, &quot;Caring for Children With Drug-Resistant Tuberculosis: Practice-Based Recommendations,&quot; <i>Am J Respir Crit Care Med</i>, 2012, 186(10):953-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22983960/pubmed\" target=\"_blank\" id=\"22983960\">22983960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &quot;Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/PMID:20034345[PubMed - indexed for MEDLINE] Free full text /pubmed\" target=\"_blank\" id=\"PMID:20034345[PubMed - indexed for MEDLINE] Free full text \">PMID:20034345[PubMed - indexed for MEDLINE] Free full text </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41:1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, (32 Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16013 Version 253.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8398365\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8398376\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8398377\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10501846\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10501924\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8408135\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8398378\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8398367\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10501964\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8404706\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10501903\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8398366\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8401456\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8401447\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8401448\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022082\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299595\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8401459\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F51073434\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8400751\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8400752\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10501965\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8404710\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8404755\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11432885\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8408137\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961985\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16013|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levofloxacin-systemic-drug-information\" class=\"drug drug_general\">Levofloxacin (systemic): Drug information</a></li><li><a href=\"topic.htm?path=levofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">Levofloxacin (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}